(Q34105271)

31 July 2017

1 reference

title

Homoharringtonine: history, current research, and future direction (English)

1 reference

ORCID Public Data File 2021

31 July 2017

1 reference

Bruce D. Cheson

5

object named as

Cheson B

1 reference

31 July 2017

Kantarjian HM

1

1 reference

31 July 2017

Talpaz M

2

1 reference

31 July 2017

Santini V

3

1 reference

31 July 2017

Murgo A

4

1 reference

31 July 2017

O'Brien SM

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

31 July 2017

1 reference

31 July 2017

92

1 reference

31 July 2017

6

1 reference

31 July 2017

1591-1605

1 reference

Cephalotaxine esters: antileukemic advance or therapeutic failure?

31 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Inhibition of Translation in Eukaryotic Systems by Harringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Cytotoxicity and cell cycle specificity of homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Homoharringtonine--perspectives on an active new natural product

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporine A and dipyridamole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Central nervous system (CNS) penetration of homoharringtonine (HHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Structures of harringtonine, isoharringtonine, and homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Antitumor Alkaloids from Cephalotaxus harringtonia: Structure and Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Quantitation of harringtonine and homoharringtonine in serum by high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Quantification of homoharringtonine and harringtonine in serum by chemical ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Quantitation of homoharringtonine in plasma by high-performance liquid chromatography with amperometric detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Homoharringtonine: a phase I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U

10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference